Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Loren K Mell, M.D

NRG Oncology

Intervention

Cetuximab(biological)

Enrollment

196 enrolled

Eligibility

18 years · All sexes

Timeline

2018 – 2025

Study locations (30)

• University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
• University of South Alabama Mitchell Cancer Institute, Mobile, Alabama, United States
• Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
• CTCA at Western Regional Medical Center, Goodyear, Arizona, United States
• Banner University Medical Center - Tucson, Tucson, Arizona, United States
• University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
• Kaiser Permanente-Deer Valley Medical Center, Antioch, California, United States
• Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
• Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
• City of Hope Comprehensive Cancer Center, Duarte, California, United States
• Kaiser Permanente Dublin, Dublin, California, United States
• Kaiser Permanente-Fremont, Fremont, California, United States
• Fresno Cancer Center, Fresno, California, United States
• Kaiser Permanente-Fresno, Fresno, California, United States
• UC San Diego Moores Cancer Center, La Jolla, California, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Canadian Cancer Trials Group · NRG Oncology

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cancer of unknown primary site

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07524114
  Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)
  University Health Network, Toronto
• RECRUITINGNANCT07283939
  Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
  Alliance for Clinical Trials in Oncology
• RECRUITINGPHASE2NCT06995508
  Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
  Roswell Park Cancer Institute
• RECRUITINGPHASE1NCT06868433
  TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
  Emory University
• RECRUITINGPHASE3NCT06589804
  Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
  National Cancer Institute (NCI)
• RECRUITINGNANCT06662058
  Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
  Emory University
• RECRUITINGPHASE2NCT06636734
  Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
  Emory University
• RECRUITINGNANCT06644716
  [18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary Origin
  Erasmus Medical Center

See all trials for Cancer of unknown primary site →